Emerging evidence has shown that the TP53 Arg/Pro polymorphism is not only associated with LC development, but also affects individual sensitivity to platinum-drug chemotherapy and patients’ survival [13]. The gene discussed is TP53; the disease is laryngotracheoesophageal cleft.